沙库巴曲缬沙坦钠联合常规药物治疗慢性心力衰竭合并高血压患者的效果

Effects of Sacubitril valsartan sodium combined with conventional medication in treatment of patients with chronic heart failure complicated with hypertension

目的:观察沙库巴曲缬沙坦钠联合常规药物治疗慢性心力衰竭合并高血压患者的效果。方法:选取2017年3月至2022年9月该院收治的106例慢性心力衰竭合并高血压患者进行前瞻性研究,按照随机数字表法分为研究组与对照组各53例。对照组采用常规药物治疗,研究组在对照组基础上联合沙库巴曲缬沙坦钠片治疗,比较两组治疗总有效率、心功能指标[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]水平、血清心肌损伤标志物[肌酸激酶同工酶(CK-MB)、肌钙蛋白、脑钠肽]水平、C反应蛋白(CRP)水平和不良反应发生率。结果:研究组治疗总有效率为96.23%,明显高于对照组的84.91%,差异有统计学意义(P<0.05);治疗后,两组LVEF水平高于治疗前,且研究组高于对照组,两组LVESD、LVEDD、CK-MB、肌钙蛋白、脑钠肽、CRP水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦钠联合常规药物治疗慢性心力衰竭合并高血压患者可提高治疗总有效率,改善心功能指标水平,降低心肌损伤标志物水平和CRP水平,效果优于单纯常规药物治疗。

Objective:To observe effects of Sacubitril valsartan sodium combined with conventional medication in treatment of patients with chronic heart failure complicated with hypertension.Methods:A prospective study was conducted on 106 patients with chronic heart failure and hypertension admitted to the hospital from March 2017 to September 2022.According to the random number table method,they were divided into study group and control group,53 cases in each group.The control group was treated with conventional medication,while the study group was treated with Sacubitril valsartan sodium tablets on the basis of that of the control group.The total effective rate,the cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)]levels,the serum myocardial injury markers[creatine kinase isoenzyme(CK-MB),troponin,brain natriuretic peptide]levels,the C-reactive protein(CRP)level,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 96.23%,which was significantly higher than 84.91%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of LVESD,LVEDD,CK-MB,troponin,brain natriuretic peptide and CRP in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sacubitril valsartan sodium combined with conventional medication in the treatment of the patients with chronic heart failure and hypertension can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of myocardial injury markers and CRP.Moreover,it is superior to single conventional medication treatment.